相关实验视频

Updated: Jan 13, 2026

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Published on: February 11, 2017

罕见的CFTR突变对特定调节器组合的反应

Noemie Stanleigh¹, Michal Gur^2,3, Michal Shteinberg^3,4

¹Department of Genetics, the Hebrew University of Jerusalem, Jerusalem, Israel.

ERJ open research

|October 29, 2025

概括

来自患者的肠道器官有效地预测对囊性纤维化转膜导电性调节器 (CFTR) 调节器疗法对罕见突变的反应. 这允许个性化治疗优化,改善临床结果并最大限度地减少不必要的药物暴露.

科学领域:

遗传学和基因组学遗传学和基因组学
药理学和治疗学药理学和治疗学
生物技术是生物技术.

背景情况:

埃莱克萨卡夫托尔-特萨卡夫托尔-伊瓦卡夫托尔 (ETI) 组合疗法有效治疗囊性纤维化转膜导电调节器 (CFTR) 突变,如F508del.
在罕见的CFTR突变上ETI的有效性仍然在很大程度上未被描述.
罕见的CFTR突变可能不需要ETI的所有组件来进行最大的功能纠正.

研究的目的:

研究ETI及其组分对罕见CFTR突变的疗效.
为了确定患者衍生的肠道器官是否可以预测对CFTR调节器治疗的反应.
为了实现针对罕见突变的CFTR调节器组合的个性化优化.

主要方法:

从患有Q1100P和/或K163E CFTR突变的患者中产生了肠道器官.
用于测量对ETI及其组件的反应,在3D有机体中使用了 Forskolin 诱导的胀和在2D单层中使用短路电流.
非标签ETI治疗是基于有机体结果开始的,临床数据是治疗前后收集的.

主要成果:

两种Q1100P和K163E突变都对ETI做出了反应,VX-445对K163E产生了显著影响.
对于这两种突变,单独使用VX-661+VX-445实现了临床显著的CFTR活性,而VX-770.0没有额外的益处.
接受非标签ETI的患者显示肺功能,体重指数和汗水化物水平持续改善.

结论:

在患者衍生肠道器官中CFTR功能测量可以确定对罕见突变的调节器疗法的潜在响应者.
这种基于器官的方法可以支持药物批准决策,并指导个性化调节器组合选择.
优化调节器组合将患者暴露于无效治疗的风险降至最低,提高治疗效率.

更多相关视频

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein

Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein

Published on: March 9, 2015

相关概念视频

Cystic Fibrosis: Management

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...

Cystic Fibrosis: Pathogenesis

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...

Mutations

Mutations